Status:
COMPLETED
Outcomes in Hepatitis C After Living Donor Liver Transplantation in Association With Interleukin 28 B
Lead Sponsor:
Henry Ford Health System
Conditions:
Hepatitis C
Eligibility:
All Genders
18+ years
Brief Summary
Hepatitis C is the leading cause of liver transplants in the USA. Given that there is a national organ shortage, living donor liver transplantation has became a viable option for patients with end sta...
Eligibility Criteria
Inclusion
- Patients who received a living donor liver transplant for chronic hepatitis C who are 18 year or older
- Patients who donated part of their liver to patients suffering from chronic hepatitis C. Donors must be 18 years or older
Exclusion
- Patients who are not willing to sign the consent
- Inability to obtain liver specimen (recipients)
- Inability to obtain blood sample (donors)
Key Trial Info
Start Date :
August 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2013
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT01429155
Start Date
August 1 2011
End Date
March 1 2013
Last Update
September 17 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Henry Ford Hospital
Detroit, Michigan, United States, 48202